ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Master Regulator SMC1A, Stabilized by N6-Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer-Promoter Interaction of Nestin.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
HCC remains a leading cause of cancer-related mortality, and effective therapies are limited. SMC1A, a core subunit of the cohesin complex involved in chromatin organization and transcriptional control, has not been fully characterized in HCC. SMC1A expression and prognostic value were analyzed using ICGC and single-cell datasets, and validated in tissue microarrays and clinical specimens. Functional roles were examined in vitro, in vivo, and in patient-derived organoids. Mechanistic studies combined transcriptomic, chromatin, and post-transcriptional analyses to define downstream transcriptional regulation and upstream m6A-dependent control. Therapeutic delivery was assessed using siRNA-loaded LNPs. SMC1A was significantly upregulated in HCC and associated with poor prognosis. SMC1A knockdown suppressed proliferation, migration, invasion, and organoid growth, reduced tumor burden in xenograft and primary models, and promoted apoptosis. Nestin was identified as a transcriptional target of SMC1A; SMC1A facilitated enhancer-promoter interactions to activate Nestin transcription, and Nestin overexpression rescued malignant phenotypes after SMC1A depletion. Upstream, IGF2BP1 bound m6A-modified regions within the SMC1A 3'-UTR, stabilized SMC1A mRNA, and maintained the SMC1A-Nestin axis. Systemic LNP-siSMC1A accumulated in the liver and inhibited tumor growth. SMC1A drives HCC progression through Nestin-associated chromatin regulation and is maintained by IGF2BP1-mediated m6A stabilization. LNP-based silencing of SMC1A suppresses HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.